Literature DB >> 11410405

The early preclinical diagnosis of osteoporosis measuring the pure trabecular bone density.

R Gass1.   

Abstract

The major skeletal determinants of fracture risk are bone mass and postmenopausal bone loss with gradual destruction of trabecular bone architecture. Therefore, the management of osteoporosis is to prevent bone loss after menopause in women below 60 years of age. We need a screening test of bone mineral density (BMD) with the ability to identify correctly individuals with accelerated bone loss; unnecessary treatment has to be avoided. But without measurable extraskeletal factors, no technique assessing BMD as single test has the reasonable high sensitivity and specificity for the diagnosis of fast bone losers. It is on principle the repeated volumetric bone measurement--within 12 months--in the pure trabecular bone, especially at distal radius of the non-dominant arm with the peripheral quantitative computed tomography (pQCT), being able to detect accurately the individuals as fast bone losers with trabecular bone loss > 8 mg/cm3 or > 3.5% per year (prevalence about 35%). Only women with very high trabecular BMD (in highest quintile) have no risk for osteoporosis.

Entities:  

Mesh:

Year:  2001        PMID: 11410405

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  3 in total

1.  Fixed-angle plates in patella fractures - a pilot cadaver study.

Authors:  M Wild; Simon Thelen; P Jungbluth; M Betsch; D Miersch; J Windolf; M Hakimi
Journal:  Eur J Med Res       Date:  2011-01-27       Impact factor: 2.175

2.  Perimenopausal Bone Loss Is Associated with Ovulatory Activity-Results of the PeKnO Study (Perimenopausal Bone Density and Ovulation).

Authors:  Teresa Starrach; Anita Santl; Vanadin Regina Seifert-Klauss
Journal:  Diagnostics (Basel)       Date:  2022-01-25

Review 3.  The aging spine: new technologies and therapeutics for the osteoporotic spine.

Authors:  Joseph M Lane; Michael J Gardner; Julie T Lin; Marjolein C van der Meulen; Elizabeth Myers
Journal:  Eur Spine J       Date:  2003-10-08       Impact factor: 3.134

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.